<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00646399</url>
  </required_header>
  <id_info>
    <org_study_id>MAB-N007</org_study_id>
    <nct_id>NCT00646399</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Pagibaximab Injection in Very Low Birth Weight Neonates for Prevention of Staphylococcal Sepsis</brief_title>
  <official_title>A Phase 2b/3, Multi-Center, Randomized, Double-Blind, Placebo Controlled Trial to Evaluate the Safety and Efficacy of Pagibaximab Injection in Very Low Birth Weight (VLBW) Neonates for the Prevention of Staphylococcal Sepsis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biosynexus Incorporated</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biosynexus Incorporated</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluate the safety, PK and efficacy comparing Pagibaximab Injection to placebo in preventing
      staphylococcal sepsis in very low birth weight infants. 1550 infants will be enrolled prior
      to 48 hours of life and will be randomized 1:1 to receive active drug or placebo on study
      days 0, 1, 2, 9, 16, and 23.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Phase 2b/3, randomized, double-blind, multicenter, placebo-controlled study evaluating the
      safety, efficacy and pharmacokinetics (PK) of pagibaximab (100 mg/kg/dose) in comparison to
      placebo for the prevention of staphylococcal sepsis in VLBW infants (600 -1200 grams).
      Subjects monitored for treatment related adverse events and tolerability to infusion of study
      drug. Neonatal sepsis will be assessed in the presence of clinical signs and symptoms and one
      blood culture positive for S. aureus or two blood cultures positive for Coagulase Negative
      Staphylococci (CoNS). The study period will be 35 days after the first dose or until, death,
      discharge, or transfer, whichever occurs first.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2009</start_date>
  <completion_date type="Actual">May 2011</completion_date>
  <primary_completion_date type="Actual">May 2011</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Number of Participants With Staphylococcal Sepsis From Study Days 0 to 35.</measure>
    <time_frame>35 days</time_frame>
    <description>Safety and efficacy</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1579</enrollment>
  <condition>Staphylococcal Sepsis</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Phosphate Buffered Saline</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pagibaximab 50 mg/mL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pagibaximab at 100 mg/kg intravenously at Days 0, 1, 2, 9, 16 and 23.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Phosphate Buffered Saline on Days 0, 1, 2, 9, 16 and 23.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pagibaximab 50 mg/mL</intervention_name>
    <description>Pagibaximab 100 mg/kg dosed on Days 0, 1, 2, 9, 16 and 23</description>
    <arm_group_label>Pagibaximab 50 mg/mL</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. In-patient at a Neonatal Intensive Care Unit (NICU)

          2. Informed consent obtained from the legally authorized representative

          3. Less than 48 hours old at the time of first infusion

          4. Birth weight between 600 grams and 1200 grams

          5. Estimated gestation age â‰¤33 weeks

        For multiple gestations, twins may be enrolled if they each meet the entry criteria. They
        will both be assigned to the same treatment group.

        Exclusion Criteria:

          1. Infants with history of a hypersensitivity or severe vasomotor reaction to any
             antibody preparation.

          2. Infants with proven staphylococcal infection prior to randomization.

          3. Infants with a concomitant infection or other medical condition, whose participation,
             in the opinion of the Investigator and/or medical advisor, may create an unacceptable
             additional risk.

          4. Immunodeficiency other than due to prematurity.

          5. Currently receiving, recently received, or planned to receive other investigational
             agents that could interfere with conduct or results of this study.

          6. Severe congenital or chromosomal anomaly that would limit life expectancy or required
             corrective measures during the period of this study

          7. Uncontrolled seizures
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>48 Hours</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Biosynexus Incorporated</name>
      <address>
        <city>Gaithersburg</city>
        <state>Maryland</state>
        <zip>20877</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.biosynexus.com</url>
    <description>Biosynexus Incorporated</description>
  </link>
  <verification_date>October 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 26, 2008</study_first_submitted>
  <study_first_submitted_qc>March 26, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 28, 2008</study_first_posted>
  <results_first_submitted>August 22, 2011</results_first_submitted>
  <results_first_submitted_qc>October 20, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 24, 2011</results_first_posted>
  <last_update_submitted>October 20, 2011</last_update_submitted>
  <last_update_submitted_qc>October 20, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 24, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Staphylococcal</keyword>
  <keyword>Coagulase Negative Staphylococcus</keyword>
  <keyword>Monoclonal antibodies</keyword>
  <keyword>Very Low Birth Weight Infants</keyword>
  <keyword>Prophylaxis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sepsis</mesh_term>
    <mesh_term>Toxemia</mesh_term>
    <mesh_term>Birth Weight</mesh_term>
    <mesh_term>Staphylococcal Infections</mesh_term>
    <mesh_term>Bacteremia</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The first subject was enrolled on 29 Mar 2009 and the last randomized subject completed the trial on 20 Jan 2011. The trial was conducted in the neonatal intensive care unit.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Pagibaximab</title>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="792"/>
                <participants group_id="P2" count="787"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="709"/>
                <participants group_id="P2" count="713"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="83"/>
                <participants group_id="P2" count="74"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="63"/>
                <participants group_id="P2" count="53"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other Reason</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Pagibaximab</title>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="792"/>
            <count group_id="B2" value="787"/>
            <count group_id="B3" value="1579"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>Gestational Age</description>
          <units>Weeks</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>600-900g</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25.7" spread="1.67"/>
                    <measurement group_id="B2" value="25.9" spread="1.83"/>
                    <measurement group_id="B3" value="25.8" spread="1.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>901-1200g</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28.0" spread="1.77"/>
                    <measurement group_id="B2" value="27.9" spread="1.73"/>
                    <measurement group_id="B3" value="28.0" spread="1.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="390"/>
                    <measurement group_id="B2" value="393"/>
                    <measurement group_id="B3" value="783"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="402"/>
                    <measurement group_id="B2" value="394"/>
                    <measurement group_id="B3" value="796"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="603"/>
                    <measurement group_id="B2" value="596"/>
                    <measurement group_id="B3" value="1199"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60"/>
                    <measurement group_id="B2" value="59"/>
                    <measurement group_id="B3" value="119"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Spain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54"/>
                    <measurement group_id="B2" value="57"/>
                    <measurement group_id="B3" value="111"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Italy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Birth Weight</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>600-900g</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="381"/>
                    <measurement group_id="B2" value="371"/>
                    <measurement group_id="B3" value="752"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>901-1200g</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="411"/>
                    <measurement group_id="B2" value="416"/>
                    <measurement group_id="B3" value="827"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Birth Weight</title>
          <units>grams</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>600-900g</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="758.8" spread="90.28"/>
                    <measurement group_id="B2" value="762.7" spread="85.05"/>
                    <measurement group_id="B3" value="760.7" spread="87.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>901-1200g</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1047.8" spread="86.25"/>
                    <measurement group_id="B2" value="1039.0" spread="85.72"/>
                    <measurement group_id="B3" value="1043.4" spread="86.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Number of Participants With Staphylococcal Sepsis From Study Days 0 to 35.</title>
        <description>Safety and efficacy</description>
        <time_frame>35 days</time_frame>
        <population>1579 very low birth weight subjects were included in the ITT.</population>
        <group_list>
          <group group_id="O1">
            <title>Pagibaximab</title>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
          </group>
        </group_list>
        <measure>
          <title>The Number of Participants With Staphylococcal Sepsis From Study Days 0 to 35.</title>
          <description>Safety and efficacy</description>
          <population>1579 very low birth weight subjects were included in the ITT.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="792"/>
                <count group_id="O2" value="787"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85"/>
                    <measurement group_id="O2" value="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Pagibaximab</title>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="284" subjects_at_risk="784"/>
                <counts group_id="E2" subjects_affected="273" subjects_at_risk="778"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="18" subjects_affected="18" subjects_at_risk="784"/>
                <counts group_id="E2" events="15" subjects_affected="14" subjects_at_risk="778"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="784"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="778"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Patent Ductus Arteriosus</sub_title>
                <counts group_id="E1" events="104" subjects_affected="104" subjects_at_risk="784"/>
                <counts group_id="E2" events="110" subjects_affected="110" subjects_at_risk="778"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Necrotizing Colitis</sub_title>
                <counts group_id="E1" events="52" subjects_affected="52" subjects_at_risk="784"/>
                <counts group_id="E2" events="42" subjects_affected="42" subjects_at_risk="778"/>
              </event>
              <event>
                <sub_title>Intestinal Perforation</sub_title>
                <counts group_id="E1" events="28" subjects_affected="28" subjects_at_risk="784"/>
                <counts group_id="E2" events="28" subjects_affected="26" subjects_at_risk="778"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="784"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="778"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Intraventricular Haemorrhage</sub_title>
                <counts group_id="E1" events="56" subjects_affected="55" subjects_at_risk="784"/>
                <counts group_id="E2" events="58" subjects_affected="57" subjects_at_risk="778"/>
              </event>
              <event>
                <sub_title>Periventricular Leukomalacia</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="784"/>
                <counts group_id="E2" events="15" subjects_affected="15" subjects_at_risk="778"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary Interstitial Emphysema</sub_title>
                <counts group_id="E1" events="27" subjects_affected="26" subjects_at_risk="784"/>
                <counts group_id="E2" events="25" subjects_affected="23" subjects_at_risk="778"/>
              </event>
              <event>
                <sub_title>Pulmonary Haemorrhage</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="784"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="778"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="770" subjects_at_risk="784"/>
                <counts group_id="E2" subjects_affected="758" subjects_at_risk="778"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="646" subjects_affected="479" subjects_at_risk="784"/>
                <counts group_id="E2" events="665" subjects_affected="487" subjects_at_risk="778"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="784"/>
                <counts group_id="E2" events="17" subjects_affected="17" subjects_at_risk="778"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrooesophageal Reflux Disease</sub_title>
                <counts group_id="E1" events="85" subjects_affected="85" subjects_at_risk="784"/>
                <counts group_id="E2" events="79" subjects_affected="79" subjects_at_risk="778"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperbilirubinaemia</sub_title>
                <counts group_id="E1" events="137" subjects_affected="128" subjects_at_risk="784"/>
                <counts group_id="E2" events="113" subjects_affected="112" subjects_at_risk="778"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Ophthalmia Neonatorum</sub_title>
                <counts group_id="E1" events="58" subjects_affected="56" subjects_at_risk="784"/>
                <counts group_id="E2" events="48" subjects_affected="41" subjects_at_risk="778"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Cardiac Murmur</sub_title>
                <counts group_id="E1" events="50" subjects_affected="48" subjects_at_risk="784"/>
                <counts group_id="E2" events="49" subjects_affected="45" subjects_at_risk="778"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Feeding Disorder Neonatal</sub_title>
                <counts group_id="E1" events="221" subjects_affected="204" subjects_at_risk="784"/>
                <counts group_id="E2" events="209" subjects_affected="194" subjects_at_risk="778"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Irwin Scher, MD</name_or_title>
      <organization>Biosynexus</organization>
      <phone>301-330-5800</phone>
      <email>irwinscher@biosynexus.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

